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Role of MYH9 and APOL1 in African and non-African
populations with lupus nephritis
CP Lin1, I Adrianto1, CJ Lessard1,2, JA Kelly1, KM Kaufman1,2,3, JM Guthridge1, BI Freedman4, J-M Anaya5, ME Alarco´n-Riquelme1,6, on
behalf of the BIOLUPUS and GENLES Networks, BA Pons-Estel7, J Martin8, S Glenn1, A Adler1, S-C Bae9, S-Y Park9, S-Y Bang9, Y-W Song10,
SA Boackle11, EE Brown12, JC Edberg12, GS Alarco´n12, MA Petri13, LA Criswell14, R Ramsey-Goldman15, JD Reveille16, LM Vila17,
GS Gilkeson18, DL Kamen18, J Ziegler19, CO Jacob20, A Rasmussen1, JA James1,2, RP Kimberly12, JT Merrill21, TB Niewold22,
RH Scofield1,2,3, AM Stevens23,24, BP Tsao25, TJ Vyse26, CD Langefeld19, KL Moser1,2, JB Harley27,28, PM Gaffney1 and CG Montgomery1
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by autoantibody production and organ
damage. Lupus nephritis (LN) is one of the most severe manifestations of SLE. Multiple studies reported associations between
renal diseases and variants in the non-muscle myosin heavy chain 9 (MYH9) and the neighboring apolipoprotein L 1 (APOL1)
genes. We evaluated 167 variants spanning MYH9 for association with LN in a multiethnic sample. The two previously identiﬁed
risk variants in APOL1 were also tested for association with LN in European-Americans (EAs) (N¼ 579) and African-Americans
(AAs) (N¼ 407). Multiple peaks of association exceeding a Bonferroni corrected P-value of Po2.03 103 were observed
between LN and MYH9 in EAs (N¼ 4620), with the most pronounced association at rs2157257 (P¼ 4.7 104, odds ratio
(OR)¼ 1.205). A modest effect with MYH9 was also detected in Gullah (rs8136069, P¼ 0.0019, OR¼ 2.304). No association
between LN and MYH9 was found in AAs, Asians, Amerindians or Hispanics. This study provides the ﬁrst investigation of MYH9 in
LN in non-Africans and of APOL1 in LN in any population, and presents novel insight into the potential role of MYH9 in LN in EAs.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a prototypic systemic
autoimmune disease characterized by multisystem involvement
and the development of an immune response against self-
antigens, leading to tissue inﬂammation, destruction and often
end-organ damage. SLE is more prevalent in females compared
with males (9:1) and in African-American (AA), Asian (AS) and
Hispanic (HI) populations compared with EuropeanAmericans
(EA).1 - 3 Patients classiﬁed with SLE manifest a minimum of 4 out
of 11 criteria set by the American College of Rheumatology4,5 with
neurological, renal and hematological manifestations representing
more severe disease. Lupus nephritis (LN) is one of the most
severe complications, drastically increasing the morbidity and
mortality of SLE patients,6 with up to 60% of adult and 80% of
pediatric SLE cases developing renal abnormalities during the
course of the disease.7,8 The incidence of LN is higher in AA, HI
and AS compared with populations of European ancestry: one
study showed that incidences of renal disease for AA and HI are
68.9% and 60.6%, respectively, compared with EA (29.1%) after 5.5
years of follow-up;9 a similar elevated incidence in AS has
also been conﬁrmed.10,11
Renal dysfunction is not an exclusive manifestation of SLE;
it is a feature of a large number of diseases that may share
underlying mechanisms or predisposing genetic factors. There
have been recent reports of genetic association of variants located
within the non-muscle myosin heavy chain 9 (MYH9) gene on
chromosome 22 and a variety of renal diseases including focal
segmental glomerulosclerosis (FSGS), HIV-associated nephropathy,
hypertension-attributed end-stage renal disease (H-ESRD) and
diabetic and non-diabetic ESRD in African-derived populations.12 - 15
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In addition, several monogenic syndromes with point mutations in
MYH9 have been characterized by thrombocytopenia, leukocyte
abnormalities and renal failure.16 Recent studies of FSGS and
H-ESRD in AAs,17,18 however, suggest that the pronounced
association of the MYH9 E-1 risk haplotype (rs4821480,
rs2032487, rs4821481 and rs3752462) is primarily due to strong
linkage disequilibrium (LD) with two independent genetic variants
(rs73885319 and rs71785313) within the neighboring apolipopro-
tein L1 (APOL1) gene.17 - 19 Although one study has assessed
association between LN and MYH9 in AAs (and found none),20 no
such study has been conducted for either MYH9 or APOL1 in non-
African populations. It was therefore the aim of this study to
investigate the role of these genes in African and non-African SLE
populations with LN. Speciﬁcally, we sought to assess association
of LN with MYH9 and evaluate the association between 2 variants
within APOL1 in EA and AA samples and 167 MYH9 variants and LN
in a large multiethnic group sample comprising of EA, AA, AS, HI,
Amerindian and Gullah (a unique AA population from the coastal
regions of South Carolina and Georgia) samples.
RESULTS
Association analysis of single-nucleotide polymorphisms (SNPs)
within MYH9 comparing LN cases and healthy controls resulted in
no signiﬁcance in the AA, HI, AS or Amerindian populations
(Figure 1, Supplementary Figure 1 and Supplementary
Table 5). The EA population yielded multiple SNPs exceeding
the Bonferroni correction (Po2.03 103) with the signiﬁcant
signals of P-valueo103 at rs2157257 (P¼ 4.7 104, odds ratio
(OR)¼ 1.205), rs5750250 (P¼ 5.4 104, OR¼ 1.472), rs2413396
(P¼ 6.74 104, OR¼ 1.327) and rs4820232 (P¼ 9.20 104,
OR¼ ¼ 1.196), all centered at approximately 35.04Mb (Figure 1
and Table 1). In addition, two of the E-1 haplotype14 SNPs
(rs4821480, rs2032487) were also below the Bonferroni signiﬁ-
cance threshold (Table 1). A modest association was also detected
in the Gullah (70 LN cases/122 healthy controls) at 35.05Mb, with
the strongest association observed at rs8136069 (P¼ 1.923 103,
OR¼ 2.304, 95% conﬁdence interval¼ 1.360--3.904). Results of
analyses comparing LN cases with SLE cases without LN were very
similar, save a slight increase in the number of signiﬁcant SNPs
(Supplementary Table 7a and b).
To further elucidate the effects observed in EA and to
determine if any particular SNP was driving the association
observed in the region independently, conditional association
analyses were performed. Based on LD (r240.8) (Figure 2),
we incorporated each of the associated SNPs in the region
with P-valueo1 103 (rs2413396, rs2157257, rs5750250 or
rs4820232) as covariates, one at a time in our model. The effect
of rs2413396 became not signiﬁcant (P41 101) when con-
ditioning on rs5750250 and the converse showed similar results
(Table 2). Similarly, the signal diminished at rs2157257 when
conditioning on rs4820232. This implies the effects of rs2413396
and rs5750250 or rs2157257 and rs4820232 are non-independent.
Both rs2413396 and rs5750250 remained signiﬁcant upon
conditioned on any of rs2157257 and rs4820232B. Likewise,
rs2157257 and rs4820232 were still signiﬁcant after conditioning
on either rs2413396 or rs5750250. Furthermore, conditioning on
both rs2157257 and rs5750250, the association signals reduced to
baseline (P41 101) (Table 2). Therefore, the two main effects
exist in the region tagged by (rs2413396, rs5750250) and
(rs2157257, rs4820232) as effect 1 and effect 2, respectively,
(Figure 2).
In order to differentiate association signals observed between
the AA and Gullah populations, we reﬁned our analysis to include
only those subjects with490% African ancestry in the AA (105 LN
cases/312 healthy controls) and Gullah (42 LN cases/69 healthy
controls) samples. The association signals in the AA and the Gullah
samples enriched for African ancestry were less signiﬁcant than
that of the full set of samples (Supplementary Figure 3), perhaps
suggesting the inﬂuence of European admixture. While we were
unable to examine variants within APOL1 in the Gullah, only a
nominal effect at rs71785313 (P¼ 0.023) of APOL1 was seen in the
AA sample (Supplementary Table 6). Note too that the association
P-values of our two genotyped SNPs within the MYH9 E-1 risk
haplotype,14 known to tag APOL1 (Supplementary Figure 2), were
also insigniﬁcant (rs4821481, P¼ 0.1759; rs3752462, P¼ 0.5104) in
AA. These results support our above conclusion of no association
between LN and either MYH9 or APOL1 in AA.
The previously reported associations of MYH9 and APOL1 with
kidney disease were described in rather homogeneous pheno-
types with severe renal failure (H-ESRD and FSGS); we speculated
that the lack of signiﬁcant association with MYH9 and APOL1 in the
AA might be due to a wider severity spectrum of renal dysfunction
associated with SLE. To explore this possibility, an analysis of a
subset of patients for whom we had information on dialysis or
kidney transplant (indicating ESRD) was performed. Fisher’s exact
tests of variants within MYH9 produced a nominally signiﬁcant
P-value of 0.041 at rs10483194 in the EA (30 LN cases/3,491
healthy controls) and P¼ 0.044 at rs739095 in the AA (67 LN cases/
1,811 healthy controls). However, we found no signiﬁcant
association within the APOL1 variants (57 LN cases/202 healthy
controls) (Supplementary Table 8). We repeated Fisher’s exact
tests using non-LN SLE as controls, results were not considerably
different, except a marginal P-value was found at an APOL1 variant
rs71785313 (P¼ 0.0418) (Supplementary Table 8). It should be
noted that even with this small sample, given the magnitude of
the ORs previously reported for APOL1,17 we had greater than 85%
power to detect an effect at a P-value of 0.01. Thus it suggests
there is no effect of APOL1 and only a slight potential for an effect
of MYH9 in LN, ESRD patients.
Finally, on the basis of a previous report of germline MYH9
mutations in a patient with SLE and end-stage renal disease,21 we
performed an exploratory analysis to address the potential role of
MYH9 in a broader class of SLE-related target organ damage.
Speciﬁcally, two subsets of SLE patients of European descent with
renal disease and/or thrombocytopenia as well as with renal
disease and/or serositis in addition to healthy controls were
evaluated for association with MYH9. The signiﬁcance of our
strongest effect at rs2413396 was increased when adding cases
with thrombocytopenia (P¼ 2.46 104, 1351 cases/3491 healthy
controls) compared with renal disease alone (P¼ 6.74 104,
1129 LN cases/3491 healthy controls), with loss of signiﬁcance
when adding patients with serositis compared with renal disease
alone (P¼ 1.86 102, 1984 cases/3491 healthy controls) (Sup-
plementary Table 9). The results of the same subgroup analyses
using non-LN SLE cases as ‘controls’ were similar, an increase in
signiﬁcance by two orders of magnitude at rs10483194 was
observed when adding cases with thrombocytopenia to the renal
diseased patients (1351 cases/1006 non-LN SLE), however, when
adding patients with serositis, signiﬁcance increased marginally as
well (1984 cases and 606 non-LN SLE) (Supplementary Table 9).
DISCUSSION
MYH9 encodes the motor protein MYH class II and isoform A, and
is expressed mainly in podocytes, peritubular capillaries and
tubules of mature kidney. It is responsible for cell polarity,
trafﬁcking and cell architecture. Dysregulation may lead to renal
complications and eventual glomerulosclerosis. It may be
implicated in SLE via its role in phagocytosis of apoptotic
leukocytes.22 Further, MYH9 is associated with a variety of diverse
syndromes that share leukocyte inclusions, abnormally large
platelets, thrombocytopenia and bleeding tendency; many of
which also include glomerulopathy with progressive renal
failure.23 - 25 More recently, MYH9 was implicated in ESRD and
FSGS in populations of African ancestry13,15,26 with even stronger
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Figure 1. Summary of association analysis for MYH9 SNPs. Plots of SNPs within the MYH9 gene associated with lupus nephritis in (a) European
American, (b) African American and (c) Gullah populations. Genotyped SNPs are represented by circles and imputed SNPs are shown in
rectangles. The recombination rate calculated from the combined CEU, YRI and JPTþCHB Hapmap data is denoted by the purple solid line.
The dotted line refers to the Bonferroni threshold of significance.
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association with two coding variants in the neighboring APOL1
gene.17,18 Its involvement in LN in AA populations has previously
been refuted, and the results of this study support this conclusion.
However, the role of MYH9 in LN in non-African populations or of
APOL1 in LN in any ethnic group has not been previously studied.
While potential weaknesses of this report include limited sample
size for the Gullah, HI and Amerindian populations and further
replication studies are needed, we interrogated the largest number
of individuals of these ethnic groups available at the time. Further,
the absence of information about dialysis and/or kidney transplant in
the medical records for the AS, Gullah, HI and Amerindian limits the
conclusions we can draw about those populations.
In summary, this report provides the ﬁrst evidence of
association between LN and MYH9 variants in a large study
Figure 2. The linkage disequilibrium for significant SNPs in European Americans. This plot shows the pair-wise LD between all markers given in
the figure. SNPs in red box represent effect 1, and SNPs in green box represent effect 2. The intensities of the LD between SNPs are depicted in
orange (effect 1), green (effect 2) and black (between effect 1 and effect 2).
Table 1. Summary results of the top 20 most significant SNPs from association analyses in European-Americans (LN cases and healthy controls) and
their respective odd ratios and confidence intervals for African-Americans and Gullah
SNPa BPb Allelec MAFd AA OR (95% CI)e Gullah OR (95% CI)e EA OR (95% CI)e EA P-valuef
rs9610486 35023388 A/G 0.310 1.011 (0.864,1.183) 1.002 (0.595,1.687) 1.178 (1.059,1.311) 2.627E-03
rs4821480g 35025193 T/G 0.043 NA NA 1.454 (1.161,1.819) 1.085E-03
rs2032487g 35025374 T/C 0.043 NA NA 1.443 (1.153,1.806) 1.364E-03
rs1009150 35032246 A/G 0.296 0.950 (0.818,1.104) 1.046 (0.657,1.665) 1.195 (1.074,1.329) 1.045E-03
rs1557530 35035568 A/G 0.328 1.045 (0.893,1.223) 0.941 (0.539,1.644) 1.177 (1.061,1.306) 2.039E-03
rs5750249 35036062 G/A 0.312 NA NA 1.191 (1.071,1.325) 1.305E-03
rs28409177 35036217 C/T 0.300 NA NA 1.180 (1.062,1.312) 2.020E-03
rs2157252 35036825 A/C 0.329 1.028 (0.885,1.194) 1.033 (0.619,1.727) 1.178 (1.061,1.307) 2.096E-03
rs2157254 35037146 C/G 0.327 1.059 (0.912,1.230) 0.995 (0.592,1.671) 1.177 (1.061,1.305) 1.993E-03
rs2157256 35037607 G/A 0.332 1.116 (0.970,1.285) 0.983 (0.612,1.581) 1.177 (1.061,1.305) 2.043E-03
rs9622377 35037819 T/C 0.331 1.056 (0.909,1.227) 1.024 (0.612,1.714) 1.174 (1.059,1.301) 2.321E-03
rs2413396 35038030 T/C 0.090 1.059 (0.924,1.213) 0.974 (0.641,1.481) 1.327 (1.127,1.562) 6.742E-04
rs2157257 35038284 G/A 0.339 NA NA 1.205 (1.085,1.338) 4.700E-04
rs5750250 35038429 A/G 0.046 1.021 (0.892,1.169) 0.945 (0.620,1.441) 1.471 (1.182,1.830) 5.403E-04
rs4820229 35038699 G/A 0.342 1.074 (0.925,1.247) 1.027 (0.618,1.704) 1.170 (1.060,1.312) 2.392E-03
rs4820230 35039485 A/G 0.327 1.092 (0.947,1.259) 0.961 (0.588,1.571) 1.170 (1.057,1.302) 2.680E-03
rs5756142 35040002 G/A 0.330 1.062 (0.915,1.232) 1.007 (0.602,1.684) 1.171 (1.056,1.299) 2.704E-03
rs4821484 35040465 A/C 0.331 1.063 (0.917,1.233) 0.972 (0.586,1.610) 1.172 (1.057,1.300) 2.519E-03
rs4820232 35040487 G/A 0.341 1.080 (0.934,1.249) 1.020 (0.625,1.663) 1.196 (1.076,1.329) 9.199E-04
rs8141971 35041308 G/A 0.332 1.042 (0.898,1.210) 0.991 (0.594,1.653) 1.172 (1.057,1.300) 2.590E-03
Abbreviations: CI, confidence intervals; EA, European-Americans; LN, lupus nephritis; MAF, minor allele frequency; NA, not applicable; OR, overall survival; SNPs,
single-nucleotide polymorphisms. aObserved SNPs were in bold. bBase pair, location in NCBI36 assembly. cAllele (major/minor). dMAF. eOR was calculated with
respect to minor allele and 95% confidence interval for OR. fAssociation results were derived using logistic regression assuming additive mode of inheritance
adjusted for global African, Asian and European ancestry estimates and gender. gE-1 haplotype SNPs were in italic.
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population of EA cases and healthy controls. Two independent
effects account for this association, located in the intronic region
approximately 31 kb away from the 30 end of MYH9. Unlike
previous studies in AAs, this signal is not explained by variants
within the neighboring APOL1 gene. The two APOL1 coding
variants accounting for association between MYH9 and renal
disease in AAs were monomorphic in the EA sample as they are
known to be present in very low frequencies (o0.5%) in general
EA populations. Moreover, results of our analyses of SLE patients
with SLE-related renal dysfunction and thrombocytopenia suggest
a broader involvement of MYH9 in lupus complications. Finally,
this report identiﬁed the ﬁrst evidence of suggestive association
between APOL1 and LN with a nominally signiﬁcant Po0.05 in
AAs. Our results highlight the complex behavior of a single gene
across multiple disorders and racial groups, suggesting the need
for additional genetic and combined gene-environment studies.
MATERIALS AND METHODS
Study populations and SNP genotyping
Independent study participants were obtained through 19 national and
international collaborators as part of the Large Lupus Association Study 2
(LLAS2). Their respective Institutional Review Boards approved all
recruitment studies. Only subjects who signed informed consent forms
were included in the study. All SLE patients fulﬁlled the revised 1997
American College of Rheumatology for classiﬁcation of SLE5 and satisﬁed
the renal criterion of either (1) persistent proteinuria40.5 g per day (24 h)
or persistent43þ if quantiﬁcation was not performed or (2) presence of
urinary cellular casts.5 The LLAS2 study included 8922 SLE cases, 3212 of
which fulﬁlled the renal ACR SLE criterion (Supplementary Table 1) and
4505 were classiﬁed as SLE without renal complication, thus comprising the
sample analyzed in this report and referred to as renal cases and non-renal
SLE cases, respectively. Renal failure documentation based on medical
record information of dialysis and/or kidney transplantation identiﬁed a
subset of 115 patients with severe LN. The control population consisted of
8077 unrelated, healthy, population-based controls with no blood relatives
with SLE, bringing the total subjects studied herein to 15794.
A total of 78 MYH9 SNPs, including eight previously associated with
ESRD,13 were genotyped in 7717 SLE cases and 8077 healthy controls from
six different ethnic groups: EA, AA, AS, HI, Amerindian and Gullah
(Supplementary Table 1). The Gullah are a population of AAs residing in the
coastal regions of South Carolina and Georgia who exhibit both unique
African ancestral origins and lesser European admixture.27 Note, that all
SNPs in the NCBI 36 database, within the MYH9 region were submitted for
inclusion in our custom genotyping assay. The 78 SNPs presented here
were those that met Illumina QC standards. All SNPs were in moderate LD
(r2 or D’o0.80) with one another. Data were generated using custom
designed Illumina iSelect Inﬁnium II genotyping arrays on the BeadStation
iScan (Illumina, San Diego, CA, USA) at the Oklahoma Medical Research
Foundation (OMRF). In addition, two APOL1 H-ESRD and FSGS risk variants
(rs73885319 (G1) and rs71785313 (G2))17 were genotyped using custom
TaqMan SNP genotyping Assays (Supplementary Method 1) in a subset of
407 AA (205 LN cases and 202 healthy controls) and 579 EA subjects (205
LN cases and 374 healthy controls) from the above cohort for which
additional DNA was available.
Quality control
To perform global ancestry estimation, a panel of 347 genomic ancestry
informative markers (Supplementary Table 2) was genotyped28,29 to
evaluate the population ancestry and any possible hidden population
substructure. The SNPs available in the MYH9 region are 650 kb away from
the nearest ancestry informative markers, and we were therefore unable to
accurately estimate the local ancestry in this region.
SNPs included in the analysis had a call rate490%, P40.001 for Hardy -
Weinberg proportion in controls, and minor allele frequencies40.001.
Samples with low call rate (o90%), sample heterozygosity outliers (45
standard deviations from the mean), extreme population outliers (based
on global ancestry estimation and principal component analysis), sample
duplicates (proportion of alleles shared identity-by-descent40.4) and
gender discrepancy between reported gender and genetic data were
excluded from analysis (Supplementary Method 2 and Supplementary
Table 3). After quality control, the ﬁnal data set comprised 77 MYH9 SNPs, 2
APOL1 SNPs, 262 ancestry informative markers, 3013 LN cases, 4262 non-
LN SLE cases and 7492 healthy controls (Table 3).
Ancestry estimation
We performed global ancestry estimation for every individual in our study
using ADMIXMAP.30 - 32 This software adopts a combination of classical and
Table 2. Summary results of conditional analysis of the significant SNPs in EA
SNP BP Single SNP P P conditional on
rs2413396 rs2157257 rs5750250 rs4820232 rs2157257 + rs5750250
rs2413396 35040002 6.74E-04 NA 2.11E-02 1.42E-01 3.11E-02 1.93E-01
rs2157257 35040129 4.70E-04 3.30E-02 NA 8.70E-03 8.01E-01 NA
rs5750250 35040465 5.40E-04 1.61E-01 3.66E-02 NA 1.10E-02 NA
rs4820232 35040487 9.20E-04 3.81E-02 6.40E-01 1.70E-02 NA 6.44E-01
Table 3. Summary of samples passing quality control
Population No. of samples Healthy controls Lupus nephritis cases Non-lupus nephritis SLE cases
African-American 3104 1811 634 659
Asian 2399 1260 529 610
European-American 6781 3491 1129 2161
Gullah 272 123 70 79
Hispanic 1274 336 439 499
Amerindian 937 471 212 254
Total 14767 7492 3013 4262
Abbreviation: SLE, systemic lupus erythematosus.
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Bayesian frameworks, and calculated ancestry information through a
Markov Chain Monte Carlo (MCMC) simulation using 262 ancestry
informative markers and the allele frequencies obtained from the HapMap
release 27. Global ancestry estimates were computed for AS, European,
Amerindian and West African ancestries.
Imputation method
Imputation was performed over a 105 kb interval ﬂanking the MYH9 gene
on chromosome 22 from 35Mb to 35.15Mb using IMPUTE2.33 - 35 A
collection of 77 SNPs was used as the source of observed genotypes and
data from the 1000 Genomes Project and the Phase III HapMap release 2
were used as the reference panels. IMPUTE2 computes posterior
probabilities for the three possible genotypes (that is, AA, AB and BB)
and then converts posterior probabilities to the most likely genotypes with
a threshold of 0.9. Imputed SNPs with low imputation accuracy
(information measure o0.5 and o90% average certainty of the most
probable genotypes) were removed from the analysis. We chose to call
genotypes so as to be able to construct haplotypes and calculate LD. We
did, however, verify that this was indeed a conservative approach by also
analyzing SNP ‘dose’ using SNPTEST36 - 38 (Supplementary Table 10). After
imputation and quality control evaluation, as described above, each data
set comprised a minimum of 89 SNPs for each of the populations (the
numbers varied based on LD structure) and is shown in Supplementary
Table 4.
Association analysis
To investigate the genotype- phenotype relationship of MYH9 and APOL1
polymorphisms in different racial groups, logistic regression including
adjustment for gender and global ancestry (quantiﬁed in terms of
European, African and AS ancestry) was performed to test for association
for MYH9 and APOL1 SNPs assuming additive, dominant and recessive
modes of inheritance using PLINK.17 - 19,39,40 We performed analyses in two
ways: (1) using healthy population-based participants as controls and (2)
using SLE, non-renal cases as controls. However, because the results were
not signiﬁcantly different, we concentrate those from the former, much
larger, data set in the main text. All reported Wald w2 P-values, 95%
conﬁdence intervals and ORs were calculated from the logistic regression
model. We controlled for experiment-wide type I error by establishing
Bonferroni correction thresholds for signiﬁcance of 2.03 103 for MYH9
and 3 102 for APOL1, based on the maximum average number of tests
across all populations and weighted for non-independence (that is,
D’40.80). Pair-wise LD measures for the MYH9 and APOL1 SNPs were
assessed by the D’ values using Haploview 4.2.41 Finally, we conducted a
conditional association analysis using PLINK,17 - 19,39,40 adjusting for gender
and global ancestry to determine whether the effects seen in EA were
independent.
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